Tscan Therapeutics Inc
Research Tscan Therapeutics Inc (TCRX) on Bullrun: market cap USD 53.82M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTCRX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 53.82M
- Financial periodQ1 2026
- RevenueUSD 982.00K
- Net income-USD 28.67M
- Free cash flow-USD 124.96M
Valuation Snapshot
latest market cap is USD 53.82M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 10.33M | -USD 129.77M | -USD 139.73M | n/a | -1 | USD 152.41M | USD 32.53M | USD 123.12M |
| FY2024 | USD 2.82M | -USD 127.50M | -USD 114.65M | n/a | -1.14 | USD 178.69M | USD 32.07M | USD 240.97M |
| FY2023 | USD 21.05M | -USD 89.22M | -USD 64.50M | n/a | -1.36 | USD 133.36M | USD 30.05M | USD 150.87M |
| FY2022 | USD 13.54M | -USD 66.22M | -USD 70.73M | n/a | -2.75 | USD 120.03M | USD 29.29M | USD 99.43M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 53.82M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 56.90M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 172.04M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 278.82M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 37.32M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 107.58M | n/a | n/a | n/a |
About Tscan Therapeutics Inc
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Tscan Therapeutics Inc's market cap?
Tscan Therapeutics Inc's market capitalization is USD 53.82M.
What does Tscan Therapeutics Inc do?
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.